|Primary Industry:||Pharma & Biotech|
|Executive Summary:||AMPI is developing nontoxic Vitamin D therapeutics for prostate cancer and other medical indications such as osteoporosis and multiple sclerosis. Recently, the National Cancer Institute awarded AMPI’s collaborators – Boston University Medical School, Boston, MA and Aphios Corporation, Woburn, MA a Phase I STTR grant to initiate development of nanosomal formulation of a nontoxic Vitamin D analog for hormone refractory prostate cancer.
Inverse relationships between incidence and mortality from various cancers, autoimmune and other diseases and dietary vitamin D are well-established. While the vitamin D hormone has strong anticancer effect in cancer cells, it is highly toxic at therapeutic doses. In vitro tests of a bromoacetate analog of the vitamin D hormone (AMPI-109) has been shown to have increased the anticancer effect while reducing systemic toxicity. This occurs through alkylation of the ligand-binding domain of vitamin D receptor in tumor cells. Furthermore, preliminary in vivo studies showed that AMPI-109 strongly reduces androgen-refractory prostate cancer in a mouse xenograft model.
Nanosomal formulation of AMPI-109 is being used to further reduce systemic toxicity, increase circulatory half-life and efficacy of AMPI-109 in prostate cancer.